Phase
Condition
Thalassemia
Birth Defects
Red Blood Cell Disorders
Treatment
RM-004
Clinical Study ID
Ages 12-35 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Subjects voluntarily sign informed consent by themselves or their legal guardiansand complete the study procedures, follow-up examination and treatment.
At the time of screening, subjects should be aged from 12 to 35 years old,regardless of gender.
History of at least 100 mL/kilograms (kg)/year of packed red blood cells (pRBC)transfusions in the prior 2 years before screening.
Subjects diagnosed with Hemoglobin H-Constant Spring disease (--/ααCS) with HBA2c.427T>C mutation.
Exclusion
Exclusion Criteria:
Subject who has an available HLA-matched/well-matched HSCT donor for allogeneichematopoietic stem cell transplantation (HSCT).
Prior HSCT or gene therapy.
History of severe hemorrhagic disease.
Clinically significant active bacterial, viral, fungal or parasitic infections perinvestigator's judgement at the time of screening.
Study Design
Study Description
Connect with a study center
The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
Nanning, Guangxi
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.